[在各种鼻病学形式的认知障碍纠正中识别 () 疗效和安全性]
O A Shavlovskaya1, I A Bokova2
1International Restorative Medicine University, Moscow, Russia.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
|November 23, 2023
概括
(Recognan) 是一种胆衍生物,具有神经保护作用,在各种条件下改善认知功能. 它有效治疗轻度认知障碍,脑血管疾病和与年龄有关的认知衰退,提供持续的神经保护.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 胆缺乏,特别是乙胆,与认知障碍 (CI) 有关.
- (Recognan) 是一个经过充分研究的胆衍生物,具有证明的神经保护性质.
- 雷康南在治疗轻度CI,慢性脑血管疾病 (CVD) 和急性血管疾病方面表现出有效性.
研究的目的:
- 审查胆 (Recognan) 的神经保护作用和治疗应用.
- 突出Recognan对各种患者群体和疾病的认知功能的好处.
主要方法:
- 审查现有关于胆的研究 (Recognan).
- 对治疗方案的分析,包括肌内,静脉和口服给药途径.
- 在不同条件下评估神经保护的持续时间和有效性.
主要成果:
- 雷科格南可以改善健康个体的记忆和认知功能,这些个体因压力,感染或情绪紧张而患有喘息症.
- 它对与年龄相关的认知衰退具有预防作用,神经保护持续6-12个月.
- 概述了针对心血管疾病和缺血性中风的具体治疗方案,包括路线和剂量调整.
结论:
- 素 (Recognan) 是一种有价值的治疗药物,用于治疗认知障碍和脑血管疾病.
- 雷康南提供显著的神经保护和认知增强在各种条件的范围,从急性事件到与年龄相关的变化.
- 灵活的注射途径 (i/m, i/v, p/o) 便于在不同的临床场景中使用它.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
128
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
128
01:30Cognitive Development During Adulthood
120
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
120
01:22Alzheimer's Disease: Treatment
196
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
196
01:26Alzheimer's Disease: Overview
496
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
496
01:30Dementia
117
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
117